$Glaukos (GKOS.US)$
Glaukos Unveils Game-Changing Vision Diagnostic Wearable: First-Ever Platform for Glaucoma Testing

$Glaukos (GKOS.US)$
Revolutionary Eye Treatment Advances: Can Glaukos Transform Keratoconus Care Without Surgery?

Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$

$Glaukos (GKOS.US)$
im seeing some decent chart upside here
thoughts?

$Ultra Nasdaq Biotechnology Proshares (BIB.US)$ was climbing 1.5%.
$SciSparc (SPRC.US)$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos (GKOS.US)$ gained 6% after We...

Gainers:
• $Canoo (GOEV.US)$ +71.3% (receives purchase order of 4500 Canoo Electric Delivery Vehicles from Walmart)
• $Aldeyra Therapeutics (ALDX.US)$ +14.1% (achieved primary endpoints in dry eye disease chamber crossover clinical trial)
• $Westport Fuel (WPRT.US)$ +10.9% (awarded 38 mln program)
• $Greenwich LifeSciences (GLSI.US)$ +5.9% (FDA has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed...